Denali Therapeutics Inc.
DNLINASDAQHealthcare● Active
$19.54
+$0.02(+0.10%)
Market Cap$3.1B
P/E Ratio—
52W High$23.77
52W Low$12.58
Denali Therapeutics Inc. (DNLI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DNLI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.69
Est. -$0.73 · +5.5%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
DNLI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.59 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.73 | -$0.69 | +5.5% | — | $0.00B | — |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.75 | -$0.73 | +2.7% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.76 | -$0.74 | +2.6% | — | $0.00B | — |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$0.74 | -$0.72 | +2.7% | — | $0.01B | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.71 | -$0.78 | -9.9% | — | $0.00B | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.75 | -$0.67 | +10.7% | — | $0.01B | — |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.60 | -$0.63 | -5.0% | — | $0.01B | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.59
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.69
EPS Est.
-$0.73
EPS Surpr.
+5.5%
Revenue
—
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.73
EPS Est.
-$0.75
EPS Surpr.
+2.7%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.74
EPS Est.
-$0.76
EPS Surpr.
+2.6%
Revenue
—
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.72
EPS Est.
-$0.74
EPS Surpr.
+2.7%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.78
EPS Est.
-$0.71
EPS Surpr.
-9.9%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.67
EPS Est.
-$0.75
EPS Surpr.
+10.7%
Revenue
—
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.63
EPS Est.
-$0.60
EPS Surpr.
-5.0%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.01 | $0.12 | $1.02 | 5 |
| Q3 FY2028 | $-0.00 | $0.02 | $0.14 | 10 |
| Q2 FY2028 | $-1.09 | $-0.12 | $0.01 | 7 |
| Q1 FY2028 | $-2.22 | $-0.25 | $0.02 | 5 |
| Q4 FY2027 | $-4.29 | $-0.49 | $0.05 | 4 |
| Q3 FY2027 | $-5.13 | $-0.58 | $0.06 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.2B | $1.6B | 6 |
| Q3 FY2028 | $0.0B | $0.2B | $1.3B | 5 |
| Q2 FY2028 | $0.0B | $0.2B | $1.1B | 5 |
| Q1 FY2028 | $0.0B | $0.1B | $0.9B | 6 |
| Q4 FY2027 | $0.0B | $0.0B | $0.3B | 6 |
| Q3 FY2027 | $0.0B | $0.0B | $0.2B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +5.5% | $20.41 | $19.71 | -3.43% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +2.7% | $22.29 | $21.42 | -3.90% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +2.6% | $14.89 | $14.41 | -3.22% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +2.7% | $13.96 | $13.92 | -0.29% |
| ▼ Q2 FY2025 | May 6, 2025 | -9.9% | $15.99 | $13.97 | -12.63% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +10.7% | $18.89 | $18.60 | -1.54% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -5.0% | $27.65 | $29.55 | +6.87% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +13.2% | $24.37 | $23.33 | -4.27% |
Q2 FY2026-3.43%
Report Date
May 7, 2026
EPS Beat/Miss
+5.5%
Price Before
$20.41
Price After
$19.71
Q1 FY2026-3.90%
Report Date
Feb 26, 2026
EPS Beat/Miss
+2.7%
Price Before
$22.29
Price After
$21.42
Q4 FY2025-3.22%
Report Date
Nov 6, 2025
EPS Beat/Miss
+2.6%
Price Before
$14.89
Price After
$14.41
Q3 FY2025-0.29%
Report Date
Aug 11, 2025
EPS Beat/Miss
+2.7%
Price Before
$13.96
Price After
$13.92
Q2 FY2025-12.63%
Report Date
May 6, 2025
EPS Beat/Miss
-9.9%
Price Before
$15.99
Price After
$13.97
Q1 FY2025-1.54%
Report Date
Feb 27, 2025
EPS Beat/Miss
+10.7%
Price Before
$18.89
Price After
$18.60
Q4 FY2024+6.87%
Report Date
Nov 6, 2024
EPS Beat/Miss
-5.0%
Price Before
$27.65
Price After
$29.55
Q3 FY2024-4.27%
Report Date
Aug 1, 2024
EPS Beat/Miss
+13.2%
Price Before
$24.37
Price After
$23.33
Avg Beat Reaction-2.77%
Avg Miss Reaction-2.88%
Beat Rate6 / 8 quarters
Largest Move-12.63% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DNLI ends December
Denali Therapeutics Inc. (DNLI) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.69 — beating the analyst consensus of $-0.73 by +5.5%. DNLI has beaten EPS estimates for 4 consecutive quarters. The next DNLI earnings date is expected around September 1, 2026.
Each quarter, investors track DNLI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DNLI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DNLI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DNLI earnings · 5 questionsDenali Therapeutics Inc.'s next earnings report is expected around September 1, 2026. DNLI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DNLI historically reports after market close (AMC).
DNLI earnings datewhen is DNLI earningsDNLI next earnings datewhen does DNLI report earningsDNLI earnings calendar
▸ Source: FMP · Denali Therapeutics Inc. SEC filings · US GAAP · Denali Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026